2024-10-18 16:58:00
The pharmaceutical laboratory should confirm the start of exclusive negotiations with the American investment fund.
The PAI fund’s offer to take control of Opella, the non-prescription medicines subsidiary (Doliprane, Maalox, Lysopaïne, etc.) of Sanofi, did not change the pharmaceutical laboratory’s mind.
On Friday 11 October Sanofi announced the start of negotiations with the CD&R fund for the repurchase of 51% of Opella. But PAI took a gamble to get back into the running, sending a revised offer to Frédéric Oudéa, chairman of Sanofi’s board of directors, on Thursday.
The French fund, allied with the sovereign wealth fund of Abu Dhabi, the Canadian British Columbia Investment and the sovereign wealth fund of Singapore, increased its offer by 200 million euros and accompanied it by guarantees on employment and production in France .
Offer “out of expiry”.
Sanofi was surprised” that a better offer is made now, outside of the deadlines and governance process that governed the decision “. The laboratory intends to continue negotiations with CD&R as if nothing had happened. A tripartite agreement with the State is being finalized, intended to guarantee the future of Opella employment and production in France, as well as the supply of the French with Doliprane.
This tripartite agreement and the official start of exclusive negotiations with the American CD&R fund are expected to be examined in the next few days, probably on Sunday, by Sanofi’s board of directors.
#Sanofi #CDR #ready #sign #tripartite #agreement #State